{"id":"nrl972","safety":{"commonSideEffects":[{"rate":null,"effect":"Respiratory tract infections"},{"rate":null,"effect":"Cough"},{"rate":null,"effect":"Gastrointestinal disturbances"}]},"_chembl":{"chemblId":"CHEMBL2107751","moleculeType":"Small molecule","molecularWeight":"926.14"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Neutrophil elastase is a serine protease released by activated neutrophils that contributes to excessive inflammation and tissue destruction in conditions like cystic fibrosis and COPD. By selectively inhibiting this enzyme, NRL972 aims to reduce pathological inflammation while preserving the antimicrobial functions of neutrophils. This targeted approach may help slow disease progression and improve lung function in chronic inflammatory airway conditions.","oneSentence":"NRL972 is a selective inhibitor of neutrophil elastase that reduces protease-mediated tissue damage in inflammatory airway diseases.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:23:30.290Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cystic fibrosis"},{"name":"Chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT00794716","phase":"PHASE2","title":"PK of NRL972 in Patients with Nonalcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD)","status":"COMPLETED","sponsor":"Norgine","startDate":"2008-06","conditions":"Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis","enrollment":125},{"nctId":"NCT01164332","phase":"PHASE1","title":"Sensitivity of Alternative NRL972 Detection Methods in Healthy Subjects","status":"COMPLETED","sponsor":"Norgine","startDate":"2010-07","conditions":"Cirrhosis","enrollment":32},{"nctId":"NCT00896597","phase":"PHASE1","title":"Reproducibility of Child-Turcotte-Pugh (CTP) Rating and NRL972 Pharmacokinetics in Patients With Cirrhosis","status":"COMPLETED","sponsor":"Norgine","startDate":"2009-04","conditions":"Hepatic Cirrhosis","enrollment":240},{"nctId":"NCT00915057","phase":"PHASE2","title":"Effect of Chronic Viral Hepatitis on the Pharmacokinetics of NRL972.","status":"COMPLETED","sponsor":"Norgine","startDate":"2009-03","conditions":"Hepatitis, Viral, Human","enrollment":100},{"nctId":"NCT00794482","phase":"PHASE3","title":"Multi-national Cirrhosis Study to Characterise the Association Between the Pharmacokinetics of NRL972 and Disease Severity.","status":"COMPLETED","sponsor":"Norgine","startDate":"2008-03","conditions":"Hepatic Cirrhosis","enrollment":1200},{"nctId":"NCT00857480","phase":"PHASE1","title":"Evaluation of the PK of NRL972 Following Pre- and co-Administration of Ursodeoxycholic Acid and Cloxacillin","status":"COMPLETED","sponsor":"Norgine","startDate":"2006-06","conditions":"Hepatic Cirrhosis","enrollment":12},{"nctId":"NCT00856713","phase":"PHASE1","title":"Clearance of NRL972 in Patients With Cirrhosis and in Healthy Volunteers","status":"COMPLETED","sponsor":"Norgine","startDate":"2006-03","conditions":"Hepatic Cirrhosis","enrollment":72},{"nctId":"NCT00856752","phase":"PHASE1","title":"Evaluation of the Pharmacokinetics of NRL972 Following Pre-Administration of Rifampicin and Cyclosporine","status":"COMPLETED","sponsor":"Norgine","startDate":"2006-06","conditions":"Pharmacokinetics","enrollment":12},{"nctId":"NCT00856869","phase":"PHASE1, PHASE2","title":"Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy Volunteers","status":"COMPLETED","sponsor":"Norgine","startDate":"2004-08","conditions":"Hepatic Cirrhosis, Nonalcoholic Steatohepatitis","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["cholyl-lysyl-fluorescein"],"phase":"phase_3","status":"active","brandName":"NRL972","genericName":"NRL972","companyName":"Norgine","companyId":"norgine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NRL972 is a selective inhibitor of neutrophil elastase that reduces protease-mediated tissue damage in inflammatory airway diseases. Used for Cystic fibrosis, Chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}